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Abstract: Herein, we present the synthesis, characterization and 
sensing behavior of a hybrid nanodevice for the detection of the 
potent abuse drug 25I-NBOMe. The system is based on 
mesoporous silica nanoparticles, loaded with a fluorescent dye, 
functionalized with a serotonin derivative and capped with the 5-HT2A 
receptor antibody. In the presence of 25I-NBOMe the capping 
antibody is displaced leading to pore opening and rhodamine B 
release. This delivery was ascribed to 5-HT2A receptor antibody 
detachment from the surface due to its stronger coordination with 
25I-NBOMe present in the solution. The prepared nanodevice 
allowed the sensitive (limit of detection of 0.6 µM) and selective 
recognition of the 25I-NBOMe drug (cocaine, heroin, mescaline, 
lysergic acid diethylamide, MDMA and morphine were unable to 
induce pore opening and rhodamine B release). This nanodevice 
acts as a highly sensitive and selective fluorometric probe for the 
25I-NBOMe illicit drug in artificial saliva and in sweets. 
In the last years, the appearance and availability of new 
psychoactive substances (NPS) in the illicit market has 
increased exponentially, becoming a serious worldwide problem 
that concerns to governments and international institutions. 
Indeed, according to the last reports published,[1] 275 million 
people, approximately 5.6% of the global population used drugs, 
at least once, in 2016. Among NPS, hallucinogenic drugs are 
proliferating and gaining popularity.  
Recently, a new synthetic family of N-
benzylphenethylamines (NBOMes) as hallucinogenic potent 
abuse drugs started to be available online. Normally, these 
drugs are consumed as a powder, in solution and in different 
supports such as blotting paper administered sublingually (in 
doses around 750 μg).[2] Moreover, these drugs have also been 
detected in adulterated commercial sweets (gummy bears), 
which are normally distributed in pubs.[3]  
One of the most remarkable members, among NBOMes 
derivatives, is 25I-NBOMe, well-known by its street names of 
“Smiles”, “Solaris”, “N-Bomb” or “Wizard”. Structurally, 25I-
NBOMe is a phenethylamine derived from the 2C family of 
NBOMes in which the 2- and 5- positions of a benzene ring have 
been substituted by methoxy groups. 25I-NBOMe, as well as 
other members of the NBOMe family, acts as extremely potent 
and highly selective agonists of the serotonin 5-HT2A receptor.
[4]
This drug is considered as a highly powerful hallucinogen in 
humans, and among its main effects can be found euphoria, 
anxiety, paranoia, memory suppression or empathy 
enhancement. Furthermore, its consumption (common dosage 
between 0.2 and 1 mg)[5] is associated with many toxicity and 
fatal cases published in the last years.[6] All these issues make 
the detection of this drug highly important. 
25I-NBOMe can be detected by several instrumental 
techniques such as HPLC-MS,[7] GC-MS,[8] differential pulse 
voltammetry,[9] ATR-FTIR spectrometry[10] and bioanalytical 
procedures.[11] However, for most of these methods, samples 
must be moved to qualified laboratories, require the use of 
complex techniques and the supervision of trained personnel 
and cannot be applied to in situ or at site analysis. In order to 
overcome these typical drawbacks of classical analytical 
techniques, the development of chemo-fluorogenic probes has 
become a matter of concern for the rapid and easy detection of 
analytes. However, as far as we know, there are not reported 
optical probes for the detection of the new drug 25I-NBOMe.  
Among different approaches to develop optical probes the 
use of hybrid organic-inorganic gated materials have been 
recently reported. These sensing hybrid probes are based on 
the use of a porous inorganic scaffold in which a reporter unit 
(usually a dye or a fluorophore) is stored and a bulky
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(supra)molecular ensemble is used as cap blocking the pores 
and inhibiting dye/fluorophore release. The capping ensemble is 
designed in such a way that interaction/coordination with a 
target analyte induces changes in its conformation/size/shape or 
is displaced, resulting in pore opening and dye/fluorophore 
release. One of the advantages of these sensing materials is the 
potential existence of amplification features. In particular, it has 
been demonstrated that the presence of few analyte molecules 
may induce the release of a relatively high amount of entrapped 
dye/fluorophore molecules.[12] As support for the development of 
such sensing hybrid materials mesoporous silica nanoparticles 
(MSNs) have been used. The main advantages provided by 
MSNs are their high specific surface area, homogeneous 
porosity, high load capacity, tunable pore size (2-10 nm) and 
easy functionalization using well-known chemistries.[13] Based on 
the above, we report herein the preparation of a selective and 
sensitive fluorogenic probe for the hallucinogen drug 25I-
NBOMe. 
The probe consists of MSNs loaded with rhodamine B, 
functionalized with a serotonin derivative (3) and capped with a 
polyclonal antibody of the 5-HT2A receptor. The nanoparticles 
are designed to show “zero” release, yet open in the presence of 
the 25I-NBOMe drug. The base of the sensing mechanism 
arises from a competition between the grafted serotonin 
derivative and 25I-NBOMe for the coordination with the antibody 
of the 5-HT2A receptor. The antibody is known to have more 
affinity for 25I-NBOMe than for the serotonin derivative and 
therefore the presence of 25I-NBOMe is expected to induce a 
displacement of the cap and selective dye delivery (Scheme 1). 
Scheme 1. Mechanism of release of solid S2 in the presence of 25I-NBOMe. 
MSNs were synthesized by base-catalyzed sol–gel 
condensation of tetraethyl orthosilicate (TEOS) in the presence 
of hexadecyltrimethylammonium bromide (CTABr) as structure 
directing agent following well-known pocedures.[14] The pores of 
the MSNs were loaded with rhodamine B (solid S0) and the 
external surface of the nanoparticles was functionalized with the 
serotonin derivative 3 (Scheme 2, S1-Boc). The Boc protecting 
group from 3 was then removed using trifluoroacetic acid (TFA), 
giving rise to the solid S1. The final probe (S2) was obtained 
after stirring a suspension of S1 containing the antibody of the 5-
HT2A receptor (see experimental details in the SI). Moreover, 
compound 3 was synthesized by the protection of the amino 
group of serotonin (1) with di-tert-butyl dicarbonate (Boc2O) to 
obtain 2[15] that was further reacted with (3-
isocyanatopropyl)triethoxysilane (Scheme 2). Compound 3 was 
characterized by using magnetic resonance techniques such as 
1H-NMR and 13C-NMR (Figures S1-S2). Furthermore, the 
nanoparticles were characterized by using standard techniques 
as powder X-ray diffraction (PXRD), transmission electron 
microscopy (TEM), N2 adsorption–desorption isotherms and 
elemental and thermogravimetric analyses (Figures S3-S6).  
The response of the sensing material S2 to the “Smiles” 
drug was evaluated. Figure 1 shows the dye release profile 
(TRIS saline Buffer at pH 7.3) from S2 obtained in the absence 
and the presence of the drug. Dye delivery was followed 
measuring the fluorescence of the rhodamine B at 572 nm at 
scheduled times in the solution. As can be seen, a large signal 
(i.e. dye delivery) was observed in the presence of 25I-NBOMe 
when compared with the same material in the absence of the 
drug. This confirms the preferential interaction of the antibody for 
25I- NBOMe that results in pore opening and cargo release. 
Scheme 2. Synthetic route used for the preparation of serotonin derivative 3. 
To further confirm that the 5-HT2A antibody plays a key role 
in the gating mechanism, we also studied the delivery profiles of 
the uncapped solid S1 in the absence and presence of 25I-
NBOMe. In this case, a marked rhodamine B release was 
observed in both cases (Figure S7). 
The sensitivity of S2 towards the “Smiles” drug was also 
tested. In this case, dye delivery from S2 in TRIS saline buffer 
towards increasing concentrations of the drug was followed. 
Figure S8 shows the gradual rise in the fluorescent emission 
with increasing concentrations of “Smiles” (each point measured 
30 min after addition). From the titration profile, a detection limit 
of 0.6 µM for 25I-NBOMe was obtained. This value is enough to 
detect a common dose (0.75 mg) even if diluted in 2 L of water. 
The response of the antibody-capped solid S2 was also 
studied against other selected drugs (Scheme 3). In particular, 
we selected lysergic acid diethylamide (LSD) because “Smiles” 
drug is used as a substitute for LSD due to its cheaper cost and 
comparable effects. Mescaline was selected because it also 
belongs to NBOMe family. Finally, the other common drugs such 
cocaine, heroin, MDMA and morphine were included in the study 
since their consumption as psychoactive drugs is highly 
extended. For this study, solid S2 was suspended in TRIS saline 
buffer at pH 7.3 in the presence of a final concentration of 75 µM 
of the drugs. As showed in Figure 2, after 20 min only 25I-
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NBOMe produces a remarkable enhancement in the emission 
fluorescence (at 572 nm) when compared with the blank 
(absence of drugs, whereas other drugs induce none or a poor 
delivery. Besides, solid S2 can be stored dried at 4 ºC for at 
least 1 month retaining, without dropping selectivity and 
sensitivity. 
Figure 1. Release profile of rhodamine B from suspensions of solid S2 in 
TRIS saline Buffer at pH 7.3, in the absence (black line) and in the presence 
(red line) of 25I-NBOMe (300 µM). Error bars are expressed as 3σ. 
In order to test the potential applicability of the probe in 
competitive environments, we tested the ability of S2 to detect 
25I-NBOMe in artificial saliva and commercial sweets. For this 
purpose, we prepared artificial saliva and measured the 
controlled release of rhodamine B from S2 nanoparticles in the 
absence and in the presence of the drug. The results obtained 
are depicted in Figure S9, which shows that even in this 
competitive medium 25I-NBOMe induced a remarkable 
uncapping of the S2 probe. Additional studies indicated that in 
artificial saliva a detection limit of 0.9 µM for 25I-NBOMe was 
obtained (Figure S10) which is a value comparable with that 
found in TRIS buffer solution.  
Figure 2. Released rhodamine B from solid S2 (measured as fluorescence 
intensity at 572 nm) in the presence of 75 µM of the indicated drugs in TRIS 
saline buffer at pH 7.3 (after 20 min of addition). Error bars are expressed as 
3σ for three independent experiments (***p<0.0001). 
For the detection of “Smiles” in adulterated candies with 
probe S2, a commercial sweet was adulterated with 5 mg of the 
drug (Figure S11). The adulterated sweet was introduced in an 
erlenmeyer flask with 10 mL of EtOH and shaken at room 
temperature for 30 minutes to extract 25I-NBOMe. As shown in 
Figure 3, rhodamine B release is significantly higher when the 
candies are adulterated. Additional studies demonstrated that 
the probe does not respond to typically component of sweet 
such as tartrazine, starch, glucose, saccharose and jelly (Figure 
S12).  
Scheme 3. Chemical structure of the drugs used as interferents for selectivity 
studies. 
Figure 3. Fluorescence emission at 572 nm (λexc= 565 nm) associated with 
rhodamine B released from S2 after 30 min of incubation with adulterated and 
non-adulterated sweet extract. Error bars are expressed as 3σ for three 
independent experiments (**p≤0.001). 
In summary, we have developed a first, rapid, highly 
selective and sensitive sensor for the fluorogenic detection of 
the synthetic drug 25I-NBOMe. The sensing material is 
synthetized using mesoporous silica nanoparticles loaded with 
rhodamine B (as a model fluorophore) and capped with 5-HT2A 
receptor antibody through its interaction with the serotonin 
derivative 3 grafted onto the external surface of the material. 
Only in the presence of 25I-NBOMe, a remarkable release of 
rhodamine B from the nanodevice is observed due to the 
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detachment of the 5-HT2A receptor antibody from the 
nanoparticle surface due to its marked affinity toward the drug. 
Furthermore, solid S2 shows a highly selective response against 
25I-NBOMe with a detection limit as low as 0.6 µM in TRIS 
saline buffer. We also demonstrated that solid S2 can be used 
for the reliable identification ‘‘in situ’’ and ‘‘at site’’ of 25I-NBOMe 
in artificial saliva and adulterated sweets. We have taken 
advantage of the use of antibodies as a promising biomolecules 
for the preparation of custom-made nanodevices for sensing 
applications. The possibility to select a countless number of 
antibodies for a number of targets makes this approach highly 
appealing. 
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